Table 3.
Results of the logistic regression model for mortality and reinfarction: crude and adjusted ORs, 95%CIs, and p-values
| EB drug therapy | OR crude | 95%CI | OR adjusted * | 95%CI | p-value |
|---|---|---|---|---|---|
| Mortality | |||||
| No EB therapy | 1.00 | 1.00 | |||
| 1 EB drug | 0.66 | 0.53–0.83 | 0.68 | 0.53–0.87 | 0.003 |
| 2 EB drugs | 0.49 | 0.39–0.61 | 0.59 | 0.47–0.76 | <0.001 |
| 3 EB drugs | 0.39 | 0.31–0.49 | 0.59 | 0.46–0.76 | <0.001 |
| Complete EB therapy | 0.23 | 0.14–0.37 | 0.35 | 0.21–0.59 | <0.001 |
| Reinfarction | |||||
| No EB therapy | 1.00 | 1.00 | |||
| 1 EB drug | 0.72 | 0.57–0.92 | 0.73 | 0.57–0.97 | 0.018 |
| 2 EB drugs | 0.49 | 0.39–0.61 | 0.49 | 0.38–0.62 | <0.001 |
| 3 EB drugs | 0.38 | 0.30–0.48 | 0.37 | 0.28–0.47 | <0.001 |
| Complete EB therapy | 0.23 | 0.15–0.35 | 0.23 | 0.15–0.37 | <0.001 |
EB, evidence based; OR, odds ratio; CI, confidence interval.
Potential confounders included in mortality analysis: PCI and bypass at index admission, heart failure, malignant neoplasm, disorders of lipoid metabolism/obesity, diabetes, chronic nephropathies, cerebrovascular disease, diseases of arteries, arterioles and capillaries, hemorrhagic stroke, hematologic diseases, cardiac dysrhythmias, duration of index admission.
Potential confounders included in re-infarction analysis: PCI and bypass at index admission, heart failure, diabetes, chronic nephropathies, diseases of arteries, arterioles and capillaries, ACE inhibitors/sartans before admission, duration of index admission.